Xona Systems, a leading provider of secure access management solutions for critical infrastructure, today announced the integration of the Xona Platform with the Nozomi Networks Arc Endpoint Sensor, ...
Boehringer Ingelheim announced today that the FIBRONEERâ„¢-ILD trial met its primary endpoint, which was the absolute change from baseline in forced vital capacity (FVC) [mL] at week 52 versus placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback